 Eli Lilly has agreed to buy U.S. gut drug maker Morphic for about $3.2 billion. Lilly will pay $57 a share in cash for Morphic, or 79% more than the closing price on Friday. For Morphic shareholders, the takeover is a turnaround after disappointing data in a clinical trial had led to a sell-off last September.